Protalix BioTherapeutics (PLX) Change in Receivables (2010 - 2026)

Protalix BioTherapeutics' Change in Receivables history runs 17 years deep, the most recent figure standing at -$6.4 million for Q1 2026.

• In Q1 2026, Change in Receivables fell 381.67% year-over-year to -$6.4 million; the TTM figure through Mar 2026 stood at -$2.8 million (down 263.91% YoY), while the FY2025 annual figure was $5.9 million, up 354.21% from the prior year.
• Change in Receivables was -$6.4 million for Q1 2026 at Protalix BioTherapeutics, down from -$5.9 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $7.1 million in Q2 2024 to a low of -$8.4 million in Q3 2024.
• Historically, Change in Receivables has averaged -$71352.9 across 5 years, with a median of $752000.0 in 2024.
• The sharpest annual moves came in 2023 and 2025: Change in Receivables jumped 254.98% in 2023, then sank 881.65% in 2025.
• A 5-year view of Change in Receivables shows it stood at -$4.5 million in 2022, then grew by 16.41% to -$3.8 million in 2023, then surged by 120.0% to $752000.0 in 2024, then tumbled by 881.65% to -$5.9 million in 2025, then retreated by 9.02% to -$6.4 million in 2026.
• The last three Change in Receivables figures came in at -$6.4 million (Q1 2026), -$5.9 million (Q4 2025), and $4.8 million (Q3 2025), per Business Quant data.